Laidlaw initiated coverage on Kazia Therapeutics with a new price target
$KZIA
Biotechnology: Pharmaceutical Preparations
Health Care
Laidlaw initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $25.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/15/2026 | $25.00 | Buy | Laidlaw |
| 2/6/2025 | $3.00 | Buy | Maxim Group |
| 10/14/2021 | $18.00 | Buy | Maxim Group |
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the appointment of Dr. Sudha Rao as Chief Scientific Officer (CSO). Dr. Rao is the scientific originator of the epigenetic framework underlying paxalisib and a pioneer in next-generation therapeutic platforms, including PD-L1 protein degradation and SETDB1-targeted chromatin modulation. Her appointment brings deep expertise in translational epigenetics, AI-guided epi-drug discovery capability, liquid and spatial epigenetic clinical biomarker precision medicine platforms, and early clinical development
SYDNEY, Australia, April 13, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The platform includes use of an AI-integrated epigenetic drug discovery engine, enabling rapid, precise, and scalable candidate generation. The lead drug candidate, MSETC, was discovered and optimized using this AI-integrated epigenetic drug discovery engine. MSETC is a highly selective bicyclic peptide designed to target a novel, disease-associated nuclear SETDB1 com
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models a
3/A - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)
Laidlaw initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $25.00
Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $3.00
Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $18.00
SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
SC 13G - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the appointment of Dr. Sudha Rao as Chief Scientific Officer (CSO). Dr. Rao is the scientific originator of the epigenetic framework underlying paxalisib and a pioneer in next-generation therapeutic platforms, including PD-L1 protein degradation and SETDB1-targeted chromatin modulation. Her appointment brings deep expertise in translational epigenetics, AI-guided epi-drug discovery capability, liquid and spatial epigenetic clinical biomarker precision medicine platforms, and early clinical development
SYDNEY, Jan. 18, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive, Mr. Robert Apple to Kazia's Board of the Directors (the "Board") as a Non-Executive Director. Mr. Apple brings more than 25 years of senior leadership experience in the pharma industry to Kazia, including 16 years with Antares Pharma, Inc. ("Antares") as Senior Vice President, Chief Financial Officer and Corporate Secretary, and went on to serve as President and Chief Executive Officer
SYDNEY, Dec. 13, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of Karen Krumeich as Chief Financial Officer. In this role, Ms Krumeich will focus on building and maintaining relationships with US investors, on preparing the company for future expansion, and on raising the profile of Kazia in global markets. Ms Krumeich is based in Pennsylvania in the United States and will formally commence work with Kazia in January 2022. Kazia CEO, Dr. James Garner, commented, "